Exane Derivatives’s Goldcorp Inc GG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-122,575
Closed -$1.4M 755
2019
Q1
$1.4M Sell
122,575
-313,189
-72% -$3.36M 0.28% 86
2018
Q4
$4.27M Buy
435,764
+320,466
+278% +$3.11M 0.77% 27
2018
Q3
$1.18M Buy
115,298
+57,818
+101% +$678K 0.22% 101
2018
Q2
$788K Buy
57,480
+7,914
+16% +$110K 0.13% 139
2018
Q1
$669K Sell
49,566
-114,407
-70% -$1.55M 0.13% 148
2017
Q4
$2.09M Buy
163,973
+55,476
+51% +$717K 0.36% 47
2017
Q3
$1.41M Sell
108,497
-1,182
-1% -$15.5K 0.26% 71
2017
Q2
$1.42M Buy
109,679
+11,532
+12% +$161K 0.3% 75
2017
Q1
$1.43M Buy
98,147
+6,157
+7% +$96.2K 0.32% 73
2016
Q4
$1.25M Buy
91,990
+57,939
+170% +$807K 0.25% 78
2016
Q3
$562K Buy
34,051
+3,797
+13% +$66.9K 0.08% 146
2016
Q2
$579K Sell
30,254
-78,907
-72% -$1.4M 0.1% 122
2016
Q1
$1.77M Buy
109,161
+53,814
+97% +$748K 0.24% 61
2015
Q4
$640K Buy
55,347
+55,235
+49,317% +$703K 0.09% 103
2015
Q3
$1.4K Sell
112
-34,981
-100% -$489K ﹤0.01% 414
2015
Q2
$568K Sell
35,093
-8,133
-19% -$148K 0.06% 134
2015
Q1
$783K Sell
43,226
-114
-0.3% -$2.43K 0.09% 110
2014
Q4
$803K Buy
+43,340
New +$889K 0.11% 112

Other funds holding GG

Exane Derivatives's GG Position: Q2 2019 in Review

Exane Derivatives sold out of Goldcorp Inc (GG) in Q2 2019, closing a stake of 122,575 shares — an estimated $1.4M sold.

Exane Derivatives first reported a position in GG in Q4 2014 and held it in 18 quarters. The position peaked at $4.27M in Q4 2018. 2 funds tracked by Wall St. Rank hold GG as of Q2 2019.

  • Exane Derivatives reported no remaining Goldcorp Inc position as of Q2 2019 after selling out during the quarter.
  • Exane Derivatives sold 122,575 Goldcorp Inc shares in Q2 2019, an estimated $1.4M.
  • Exane Derivatives first reported a position in Goldcorp Inc in Q4 2014 and held it in 18 quarters.
  • Exane Derivatives's Goldcorp Inc position peaked at $4.27M in Q4 2018.
  • 2 funds tracked by Wall St. Rank held Goldcorp Inc as of Q2 2019.

Based on Exane Derivatives's 13F filing for Q2 2019, filed 12 Jul 2019.